ARS Pharmaceuticals, Inc (SPRY) — Capital Reinvestment Ratio
ARS Pharmaceuticals, Inc (SPRY) has a Capital Reinvestment Ratio of 0.01x as of December 2024, meaning it reinvests 0% of its operating cash flow ($42.00 Million) in capital expenditures ($302.00K). See ARS Pharmaceuticals, Inc balance sheet quality to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
ARS Pharmaceuticals, Inc Capital Reinvestment Ratio (2020–2024)
This chart tracks ARS Pharmaceuticals, Inc's Capital Reinvestment Ratio across 2 annual periods. Check how aggressively does ARS Pharmaceuticals, Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for ARS Pharmaceuticals, Inc (2020–2024)
Year-by-year Capital Reinvestment Ratio for ARS Pharmaceuticals, Inc from 2020 to 2024. For live market cap and broader valuation context, see SPRY market cap overview.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.04x | $13.55 Million | $563.00K | ▼ -58.9% |
| 2020 | 0.10x | $9.07 Million | $917.00K | — |